- Home
- SVRA
SVRA
Savara Inc.
as 10-04-2024 4:00pm EST
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 739.1M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.12 - $5.70 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Savara Inc. News
SVRA Breaking Stock News: Dive into SVRA Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
MT Newswires
8 days ago
Savara Initiates Early Access Program for Rare Lung Disease Treatment
Business Wire
8 days ago
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire
11 days ago
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
Business Wire
12 days ago
Savara to Host Analyst and Investor Webinar on September 30, 2024
MT Newswires
a month ago
Savara's Lung Disease Therapy Improves Disease Severity Score in Phase 3 Study
Business Wire
a month ago
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Business Wire
a month ago
Savara Announces New Employment Inducement Grant
Compare SVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SVRA Savara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.